Australian-based pharmaceutical companies have begun submitting higher reimbursement prices in applications to the PBAC, with some explicitly using US list prices, while Pfizer has announced an agreement with the Trump administration "that will ensure US patients pay lower prices". …
New pricing dynamics emerging for Australia as Pfizer signs up to US 'MFN'
October 1, 2025 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
New Zealand identified as a ‘major outlier’ in OECD medicines investment
October 24, 2025 - - BioPharma -
A perspective that rightly belongs in a time capsule from the 1990s
October 23, 2025 - - Latest News -
Global focus intensifies as AusBiotech strengthens trade, partnerships and international engagement
October 23, 2025 - - Australian Biotech -
Queensland resources sector backs prevention-first health push to boost workforce productivity
October 23, 2025 - - Latest News -
Omico appoints Richard Vines as new Chair as it strengthens national precision oncology agenda
October 23, 2025 - - Latest News -
Island Pharmaceuticals secures FDA response date for Galidesivir approval pathway
October 23, 2025 - - Australian Biotech -
Noxopharm granted first US patent for Sofra immune-modulation platform
October 23, 2025 - - Australian Biotech